ResearchMoz

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2013-03-13
No. Of Pages » 128
 
   
 Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules...
Table of content

Chapter 1 Introduction
1.1 Report description
1.2 Market segmentation
1.3 Scope of the report
1.4 Research methodology
1.5 Assumptions

Chapter 2 Executive Summary
2.1.1 Global peptide therapeutics market revenues, 2010 – 2018 (USD Million)
2.1.2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million)
2.1.3 Global API peptide therapeutics market, 2011 (USD Million)
2.1.4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%)

Chapter 3 Global Peptide Therapeutics Market Dynamics
3.1 Overview
3.2 Drivers
3.2.1 Increase in cancer patient population to propel the growth of new peptides
3.2.2 Rise in metabolic disorders to escalate the growth of peptides market
3.2.3 Rise in R&D pipeline of peptide drugs is expected to bring considerable growth in coming years
3.2.3.1 Global peptide therapeutics trials growth, 1970 - 2011
3.2.4 Technological enhancement has boosted the growth of the market with radical reduction in total production cost of peptides
3.3 Restraints & challenges
3.3.1 Increasing complexity of peptides is a huge challenge for manufacturers
3.3.2 Lack of regulatory standards hampering the growth of the market
3.3.3 Matching equipments with customer requirements is a major challenge for API peptide manufacturers
3.4 Opportunities
3.4.1 Rise in cancer vaccine to drive the future market
3.4.2 Generic peptides market to flourish with patent cliff expected in the forecast period
3.4.3 Small biotech firms collaborating with large pharmaceutical companies to explore further growth
3.4.3.1 Global scenario of acquisitions of biotech firms by large pharma giants
3.4.3.2 Major peptide drugs and sales, 2011 (USD Million)
3.5 Porters five forces analysis
3.5.1 Porter’s five forces analysis of global peptide therapeutics market
3.5.2 Bargaining power of suppliers
3.5.3 Bargaining power of buyers
3.5.4 Threat of new entrants
3.5.5 Threat of substitutes
3.5.6 Competitive rivalry
3.6 Market attractiveness analysis
3.6.1 Market attractiveness analysis of the peptide therapeutics market by geography
3.7 Peptide therapeutics - emerging technologies & trends
3.8 Regulatory policies

Chapter 4 Global Peptide Therapeutics Market Analysis, By Applications
4.1.1 Introduction
4.1.1.1 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million)
4.1.2 Cancer
4.1.2.1 Global cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.2.2 Global cancer peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.3 Metabolic
4.1.3.1 Global metabolic peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.3.2 Global metabolic peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.4 Cardiovascular
4.1.4.1 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.4.2 Global cardiovascular peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.5 Dermatology
4.1.5.1 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012
4.1.5.2 Global dermatology peptides market revenues, 2010 – 2018 (USD Million)
4.1.6 Anti-Infection
4.1.6.1 Global anti-infection drugs analysis, number of trials, 2009 - 2012
4.1.6.2 Global anti-infection peptides market revenues, 2010 – 2018 (USD Million)
4.1.7 Neurology
4.1.7.1 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012
4.1.7.2 Global neurology peptides market revenues, 2010 – 2018 (USD Million)
4.1.8 Gastro Intestinal
4.1.8.1 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012
4.1.8.2 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million)
4.1.9 Renal
4.1.9.1 Global renal pipeline drugs analysis, number of trials, 2009 - 2012
4.1.9.2 Global renal peptides market revenues, 2010 – 2018 (USD Million)
4.1.10 Respiratory
4.1.10.1 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012
4.1.10.2 Global respiratory peptides market revenues, 2010 – 2018 (USD Million)
4.1.11 Pain
4.1.11.1 Global pain pipeline drugs analysis, number of trials, 2009 - 2012
4.1.11.2 Global pain peptides market revenues, 2010 - 2018 (USD Million)
4.1.12 Others
4.1.12.1 Global other pipeline drugs analysis, number of trials, 2009 - 2012
4.1.12.2 Global other peptides market revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.1.1 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million)
5.1.2 Methods of delivery for peptide drugs
5.2 Parenteral Route
5.2.1 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million)
5.3 Oral Route
5.3.1 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million)
5.4 Pulmonary Route
5.4.1 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million)
5.5 Mucosal Route
5.5.1 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million)
5.6 Others (Intradermal & Nasal)
5.6.1 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million)

Chapter 6 Peptide Therapeutics Market – Generic & Innovative Segments
6.1 Introduction
6.1.1 Global peptide therapeutics market, by types revenues, 2010 - 2018 (USD million)
6.2 Peptide Therapeutics – Innovative market
6.2.1 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million)
6.3 Peptide Therapeutics – Generic market
6.3.1 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million)

Chapter 7 API Peptide Therapeutics Market, In-house Vs CMO
7.1 Introduction
7.2 API peptide therapeutics – In-house market
7.2.1 Global API peptide therapeutics in-house market revenues, 2010-2018 (USD Million)
7.3 Contract Manufacturing Organizations (CMO)
7.3.1 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million)

Chapter 8 Peptide Therapeutics Market, By Technology
8.1 Introduction
8.1.1 Global peptide therapeutics market revenues, by technology, 2010 – 2018 (USD Million)
8.2 Solid Phase Peptide Synthesis (SPPS)
8.2.1 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.3.1 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million)
8.4 Hybrid Technology
8.4.1 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million)

Chapter 9 Peptide Therapeutics Market, By Geography
9.1 Introduction
9.1.1 Global peptide therapeutics market share, by geography, 2011 - 2018
9.2 North America
9.2.1 North America peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.3 Europe
9.3.1 Europe peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.4 Asia 
9.4.1 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million)
9.5 Rest of World
9.5.1 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million)

Chapter 10 Market Share Analysis
10.1 Market share by key players
10.2 Market share by key players in peptide drugs market
10.2.1 Global peptide therapeutics market share analysis of key players, 2011 (%)
10.3 Market share by key players in CMO segment
10.3.1 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%)

Chapter 11 Recommendations
11.1 Success strategies
11.1.1 Rigorous research and development (R&D) initiatives
11.1.2 Investing in emerging economies
11.1.3 Investing in recent technologies such as HPPS TEchnology
11.1.4 Mergers and acquisitions
11.2 Barriers to be considered
11.2.1 The high cost of peptide synthesis
11.2.2 Weak pipeline peptide drug candidates in phase III

Chapter 12 Company Profiles
12.1 Bachem Holding AG
12.1.1 Company overview
12.1.2 Financial overview
12.1.3 Strategic overview
12.1.3.1 Collaborations
12.1.3.2 Expansion
12.1.3.3 Divestiture
12.1.3.4 Recent developments
12.2 Eli Lilly and Company
12.2.1 Company overview
12.2.2 Financial overview
12.2.3 Strategic overview
12.2.3.1 Agreements
12.2.3.2 Approvals
12.2.4 Recent developments
12.3 Pfizer, Inc.
12.3.1 Company overview
12.3.2 Financial overview
12.3.3 Strategic overview
12.3.3.1 Mergers and acquisitions
12.3.3.2 Divestiture
12.3.3.3 Approvals
12.3.4 Recent developments
12.4 Amgen, Inc.
12.4.1 Company overview
12.4.2 Financial overview
12.4.3 Strategic overview
12.4.3.1 Mergers and acquisitions
12.4.3.2 Licensing
12.4.4 Recent developments
12.5 Takeda Pharmaceutical Company Limited
12.5.1 Company overview
12.5.2 Financial overview
12.5.3 Strategic overview
12.5.3.1 Partnerships and collaborations
12.5.3.2 Mergers and acquisitions
12.5.4 Recent developments
12.6 Teva Pharmaceuticals
12.6.1 Company overview
12.6.2 Financial overview
12.6.3 Strategic overview
12.6.3.1 Mergers and acquisitions
12.6.3.2 Investing in generic and biosimilar segments
12.6.4 Recent developments
12.7 Lonza Inc.
12.7.1 Company overview
12.7.2 Financial overview
12.7.3 Strategic overview
12.7.3.1 Investing in emerging economies
12.7.3.2 Mergers and acquisitions
12.7.4 Recent developments
12.8 Peptisyntha
12.8.1 Company overview
12.8.2 Financial overview
12.8.3 Strategic overview
12.8.3.1 Arranging and participating in trade shows
12.8.3.2 Continuous manufacturing expansion
12.9 Sanofi
12.9.1 Company overview
12.9.2 Financial overview
12.9.3 Strategic overview
12.9.3.1 Acquisitions
12.9.3.2 Divestments
12.9.4 Recent developments
12.10 Ipsen
12.10.1 Company overview
12.10.2 Financial overview
12.10.3 Strategic overview
12.10.3.1 Large investment in research and development
12.10.3.2 Global expansion through partnership
12.10.4 Recent developments
12.11 PolyPeptide Group.
12.11.1 Company overview
12.11.2 Strategic overview
12.11.2.1 Focus on product portfolio extension and quality product development
12.11.2.2 Global expansion through merger and acquisition
12.12 Amylin Pharmaceuticals LLC - Bristol-Myers Squibb (BMS)
12.12.1 Company overview
12.12.2 Amylin Pharmaceuticals LLC
12.12.3 Financial overview
12.12.4 Strategic overview (Amylin Pharmaceuticals LLC)
12.12.4.1 Entering into strategic collaborations
12.12.4.2 Corporate social responsibility
12.12.4.3 Rigorous R&D initiatives
12.12.5 Recent developments
12.13 AstraZeneca PLC
12.13.1 Company overview
12.13.2 Financial overview
12.13.3 Strategic overview
12.13.3.1 Rigorous R&D initiatives
12.13.3.2 Investing in emerging economies
12.13.4 Recent developments
12.14 Roche
12.14.1 Company overview
12.14.2 Financial overview
12.14.3 Strategic overview
12.14.3.1 Research and development initiatives
12.14.3.2 Focus on personalized healthcare
12.14.3.3 Focus on new and emerging markets
12.14.3.4 Funding awareness programs
12.14.4 Recent developments
12.15 GlaxoSmithKline (GSK)
12.15.1 Company overview
12.15.2 Financial overview
12.15.3 Strategic overview
12.15.3.1 Research and development initiatives
12.15.3.2 Direct to Consumer Advertising
12.15.3.3 Mergers and acquisitions
12.15.4 Recent developments
12.16 Merck & Co.
12.16.1 Company overview
12.16.2 Financial overview
12.16.3 Strategic overview
12.16.3.1 Corporate social responsibility
12.16.3.2 R&D Initiatives
12.16.3.3 Strategic alliances and out-licensing
12.16.4 Recent developments
12.17 Novartis AG
12.17.1 Company overview
12.17.2 Financial overview
12.17.3 Strategic overview
12.17.3.1 Mergers and acquisitions
12.17.3.2 Memorandum of understanding
12.17.4 Recent developments
12.18 Novo-Nordisk A/S
12.18.1 Company overview
12.18.2 Financial overview
12.18.3 Strategic overview
12.18.3.1 Partnerships and alliances
12.18.4 Agreements
12.18.5 Recent developments

List of Tables


TABLE 1 Global therapeutic peptides market: Snapshot 22
TABLE 2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million) 23
TABLE 3 Global scenario of acquisitions of biotech firms by large pharma giants 31
TABLE 4 Major peptide drugs and sales, 2011 (USD Million) 31
TABLE 5 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million) 36
TABLE 6 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million) 56
TABLE 7 Methods of delivery for peptide drugs 57
TABLE 8 Global peptide therapeutics market, revenues, by types 2010 - 2018 (USD million) 63
TABLE 9 Global API peptide therapeutics Market, By Revenue, by Types, 2010 - 2018 (USD million) 67
TABLE 10 Global peptide therapeutics market revenues, by technology, 2010 - 2018 (USD Million) 70
TABLE 11 Global Peptide Therapeutics Market, By Geography, 2010-2018 (USD Million) 75

List of Figures


FIG. 1 Global Peptide Therapeutics: Market Snapshot 18
FIG. 2 Global peptide therapeutics market, by revenue, 2010 – 2018 (USD Million) 23
FIG. 3 Global API peptide therapeutics market, 2011 (USD Million) 24
FIG. 4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%) 25
FIG. 5 Global peptide therapeutics trials growth, 1970 - 2011 27
FIG. 6 Porter’s five forces analysis for global peptide therapeutics market 32
FIG. 7 Market attractiveness analysis of the global peptide therapeutics market, by geography 34
FIG. 8 Global Cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 38
FIG. 9 Global cancer peptide therapeutics market revenues, 2010 - 2018 (USD Million) 39
FIG. 10 Global metabolic peptide therapeutics pipeline drugs analysis , number of trials, 2009 - 2012 40
FIG. 11 Global metabolic peptide therapeutics market revenues, 2010 - 2018 (USD Million) 40
FIG. 12 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 41
FIG. 13 Global cardiovascular peptide therapeutics market revenues, 2010 - 2018 (USD Million) 42
FIG. 14 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012 43
FIG. 15 Global dermatology peptides market revenues, 2010 - 2018 (USD Million) 44
FIG. 16 Global anti-infection pipeline drugs analysis, number of trials, 2009 - 2012 45
FIG. 17 Global anti-infection peptides market revenues, 2010 - 2018 (USD Million) 46
FIG. 18 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012 47
FIG. 19 Global neurology peptides market revenues, 2010 - 2018 (USD Million) 47
FIG. 20 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012 48
FIG. 21 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million) 49
FIG. 22 Global renal pipeline drugs analysis, number of trials, 2009 - 2012 50
FIG. 23 Global renal peptides market revenues, 2010 - 2018 (USD Million) 50
FIG. 24 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012 51
FIG. 25 Global respiratory peptides market, revenues, 2010 - 2018 (USD Million) 52
FIG. 26 Global pain pipeline drugs analysis, number of trials, 2009 - 2012 53
FIG. 27 Global pain peptides market revenues, 2010 - 2018 (USD Million) 53
FIG. 28 Global others pipeline drugs analysis, number of trials, 2009 - 2012 54
FIG. 29 Global others peptides market revenues, 2010 - 2018 (USD Million) 55
FIG. 30 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million) 58
FIG. 31 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million) 59
FIG. 32 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million) 60
FIG. 33 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million) 61
FIG. 34 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million) 62
FIG. 35 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million) 65
FIG. 36 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million) 66
FIG. 37 Global API peptide therapeutics in-house market revenues, 2010 - 2018 (USD Million) 68
FIG. 38 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million) 69
FIG. 39 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million) 71
FIG. 40 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million) 72
FIG. 41 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million) 73
FIG. 42 Global peptide therapeutics market, by geography, 2011 - 2018 74
FIG. 43 North America peptide therapeutics market revenues, 2010 - 2018 (USD Million) 76
FIG. 44 Europe peptide therapeutics market revenues, 2010 - 2018 (USD Million) 77
FIG. 45 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million) 78
FIG. 46 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million) 79
FIG. 47 Global peptide therapeutics market share analysis of key players, 2011 (%) 81
FIG. 48 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%) 82
FIG. 49 Bachem Holding AG: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 87
FIG. 50 Eli Lilly & Company: annual revenues, 2009 – 2011 (USD Million) 89
FIG. 51 Pfizer, Inc.: annual revenues, 2009 – 2011 (USD Million) 91
FIG. 52 Amgen, Inc.: annual revenues, 2009 – 2011 (USD Million) 94
FIG. 53 Takeda Pharmaceutical Company Ltd.: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 JPY = 0.01 USD) 97
FIG. 54 Teva Pharmaceuticals: annual revenues, 2009 – 2011 (USD Million) 99
FIG. 55 Lonza Inc.: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 101
FIG. 56 Solvay Group: annual revenues, 2010 – 2011 (USD Million) (conversion rate: 1 Euro = 1.34 USD) 103
FIG. 57 Sanofi: annual revenues, 2009 – 2011 (USD Million) 105
FIG. 58 Ipsen: annual revenue Share, by geography, 2010 & 2011 (%) 107
FIG. 59 Ipsen: annual revenues, 2009 - 2011 (USD Million) 108
FIG. 60 Bristol-Myers Squibb: annual revenues, 2009 – 2011 (USD Million) 112
FIG. 61 AstraZaneca PLC: annual revenues, 2009 – 2011 (USD Million) 114
FIG. 62 Roche: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 116
FIG. 63 GSK: annual revenues, 2009 – 2011 (USD million) (conversion rate: 1 GBP = 1.5849 USD) 118
FIG. 64 Merck & Co.: annual revenues, 2009 – 2011 (USD Million) 120
FIG. 65 Novartis AG: annual revenues, 2009 – 2011 (USD Million) 123

Upcoming Reports:

Greece: market of pumpkins, squash and gourds
By - Williams and Marshal Strategy
ash and gourds market in Greece includes: Analysis and dynamics of the economy of Greece; Forecast for the development of the economy of Greece; Analysis and forecast of market volume and dynamics; Volume, dynamics and analysis of domestic production; Characteristics of market structure (by origin, by types of products, etc.); Analysis of price level and dynamics; Volume, dynamics and analysis of imports; Volume, dynamics and analysis of exports; Volume, dynamics and analysis of consumption; Characteristics of the main market participants (manufacturers, importers and exporters);...
E-Paper Display Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Electronic paper technology is mainly used for the development and ease of e-book readers. This market has grown in recent years with successful advancement in E-paper display devices. Benefits offered by E-paper technology include lower power consumption in addition with sunlight readability. This results in an enhanced performance. E-paper display technology is capable to compete with the established and mature display technologies such as LCD. Widespread availability of e-paper and devices based on it are expected to impact the paper industry as it could lead paper industry to...
GPON Equipment Market - Global Industry size, market share, trends, analysis and forecasts 2012 - 2018
By - Transparency Market Research
Passive optical network (PON) is a network architecture that brings fiber cabling and signals to home using point to multipoint scheme that enables single optical fiber to serve multiple premises. This architecture makes use of passive optical splitters that helps in reducing cost of equipments compared to point to point architecture.  Gigabit passive optical network (GPON) standard differs from other PON standards as it offers better bandwidth and higher efficiency using larger, variable length packets. GPON equipment market is expected to witness significant growth in...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Low Gas Prices Hurt Utahs Energy Industry
Dec 18, 2014  
Due to excessive petroleum on the global market, gas prices are heavily tumbling in several places of the world. This aspect could prove effective and great for consumers in most parts of the world, but it is not so for the Utah. The petroleum industry in Utah has a tough time with the state budget.  In Utah, the average gas prices have declined to around $2.64 a gallon. This has...
The 3 Dining Trend to Look Out For in 2015
Dec 17, 2014  
Dining is a vibrant, dynamic subject. You can never set down a list of definitive rules for it, and since it depends on our own fickle taste, it is always subject to drastic changes and welcoming to new trends. Here’s a list of dining trends that are on the cusp of becoming mainstream and will surely make that step up in the coming year. 1. Increasing Acceptance of Technology:...
Bolivian Air Force Receives the Super Puma Helicopters
Dec 16, 2014  
It was declared by the Airbus Helicopters that the Bolivian Air Force was the recipient of second of the six Airbus AS332 C1e Super Puma helicopters. The Super Pumas are generally used for several internal security missions and counter narcotics. The rest of the four helicopters will start operating from the year 2016. In late 2013, the light medium helicopters were purchased by the FAB for...
Leaked Emails Prove to be Challenging for Sony
Dec 15, 2014  
It has been revealed via leaked emails that there exists a cultural gulf between Sony Pictures Entertainment, the Hollywood subsidiary on the one hand and Japan’s Sony Corp on the other. This poses a major challenge to the CEO Kazuo Hirai to bring about positive changes in the loss making company under the One Sony slogan.  Over the past six years, this has been the fifth...
British Construction Firms to Hire More by 2015
Dec 10, 2014  
As per the latest survey carried out by Manpower, increasing workload in Britain’s construction industry is calling for rise in employment opportunities. It is expected that in the coming year, various construction firms will be on a hiring spree. Paucity of trained and skilled workers in U.K. based building firms has led to greater focus on hiring of Portuguese bricklayers at a wage...